Pennsylvania boasts over 500K patients, making it the second-largest medical market. Pennsylvania awarded 50 licenses that allow for three dispensaries per license and 25 processors, five of which can be vertically integrated. Operators are allowed up to five retail licenses, for a total of 15 dispensaries. Qualifying medical conditions include chronic pain and anxiety, making this one of the least restrictive environments.

Pennsylvania also implemented a Clinical Research ("CR") license program. Program guidelines note that eight CR licenses will be issued to operators who are partnered with one of Pennsylvania's major university health institutions. Each of the eight license holders can operate up to six dispensaries and one cultivation site.

July 2021 the law was amended to allow patients to increase their basket size to a three month supply and permanently allowing curbside dispensing.

Notably, Governor Tom Wolf (D) is supportive of an adult-use program, and with Pennsylvania turning blue in the 2020 election, adult-use is more likely than ever. Watch for a ballot initiative here.

May 2021 | GTI acquires NSE , The Healing Center & TerraVida

November 2020 | Trulieve acquires PurePenn & Solevo

August 2020 | Ayr reaches an agreement to acquire and develop six retail dispensaries and a significant cultivation and production footprint in a limited license state for total consideration of $57MM

November 2019 | Harvest Health acquires CannaPharmacy
‍

The play in the Quaker State is to build out infrastructure in anticipation of adult-use. Through the new Clinical Research program, 200 dispensaries will ultimately be allowed in this market. That said, no single operator can own more than 15 total, which should allow for relatively broad market participation.

Dispensaries should look to maximize earnings in advance of selling/partnering with one of the 25 cultivators in need of retail presence. Cultivators currently hold the power in this market, with wholesale flower prices in the $4K per pound range. We don't anticipate an oversupply to impact pricing in the near-term, but the market will need adult-use to avoid such a fate. Expect the recently-seen flurry of acquisitions here to continue for the foreseeable future.